surmount studies tirzepatide ECO 2026: SURMOUNT-MAINTAIN proves sustains weight loss long term Tirzepatide for the Treatment of

Between 2017-18 and 2022-23, the total prescription drug spending for Canadas public drug plans rose by more than $3 billion to a grand total of over $14 billion

Injectable GLP-1 medications currently have a stronger and more established evidence base for weight loss, but oral options are showing meaningful results in clinical trials: In the head-to-head SURMOUNT-5 trial, researchers reported injectable tirzepatide had a mean weight reduction of about 20.2% at 72 weeks, compared with roughly 13.7% for injectable semaglutide

Key examples include: Stimulant-containing supplements (caffeine, synephrine, yohimbine) should be avoided by people taking MAOIs or with uncontrolled hypertension Glucomannan may reduce the absorption of oral medicines

Reach out for support if you need it, either by opening up to friends and family or connecting with a therapist

In studies, 4% to 8% of patients stopped treatment due to side effects such as nausea, vomiting, and/or diarrhea